Neurocrine Biosciences, Inc. (NBIX) News
Filter NBIX News Items
NBIX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NBIX News Highlights
- NBIX's 30 day story count now stands at 20.
- Over the past 22 days, the trend for NBIX's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
- The most mentioned tickers in articles about NBIX are TD, AMP and CAH.
Latest NBIX News From Around the Web
Below are the latest news stories about NEUROCRINE BIOSCIENCES INC that investors may wish to consider to help them evaluate NBIX as an investment opportunity.
Investors one-year returns in Neurocrine Biosciences (NASDAQ:NBIX) have not grown faster than the company's underlying earnings growthIt hasn't been the best quarter for Neurocrine Biosciences, Inc. ( NASDAQ:NBIX ) shareholders, since the share price... |
Neurocrine Biosciences to Present at the SVB Securities Global Biopharma ConferenceNeurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the virtual SVB Securities Global Biopharma Conference at 12:00 p.m. Eastern Time on Tuesday, February 14, 2023. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the conference. |
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2022 Earnings Call TranscriptNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2022 Earnings Call Transcript February 6, 2023 Operator: Good day, everyone, and welcome to today’s Neurocrine Biosciences Reports Fourth Quarter and Year End Results. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question-and-answer session. . Please note […] |
Neurocrine Biosciences, Inc. (NBIX) Q4 2022 Earnings Call TranscriptStart Time: 08:00 End Time: 09:02 Neurocrine Biosciences, Inc. (NBIX) Q4 2022 Earnings Conference Call February 06, 2023, 08:00 AM ET Company Participants Kevin Gorman - CEO Matt Abernethy - CFO Eric Benevich - Chief Commercial Officer Eiry Roberts - Chief Medical Officer Kyle Gano - Chief Business Development and Strategy Officer Todd Tushla - VP of IR Conference Call Participants Paul Matteis - Stifel Neena Bitritto-Garg - Citi Tazeen Ahmad - Bank of America Brian Skorney - Baird Phil Nadeau - Cowen & Company Chris Shibutani - Goldman Sachs Carter Gould - Barclays Myles Minter - William Blair Brian Abrahams - RBC Capital... |
Neurocrine Reports 3,000% Profit Growth, But Shares Unexpectedly TumbleNeurocrine reported soaring fourth-quarter profit Monday and issued in-line guidance for Ingrezza. But NBIX stock toppled. |
If You're in Neurocrine Biosciences Consider Getting Out: Here's WhyPrices declined below $106 in early trading Monday so traders should be out of longs. The On-Balance-Volume (OBV) line has stalled the past three months. The trend-following Moving Average Convergence Divergence (MACD) oscillator is bearish. |
Neurocrine Biosciences (NBIX) Lags Q4 Earnings EstimatesNeurocrine (NBIX) delivered earnings and revenue surprises of -23.48% and 0.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? |
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided financial guidance for 2023. |
Catalent (CTLT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseCatalent (CTLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |